Premium
Nicotinic Receptor‐Mediated Release of Noradrenaline in the Human Neuroblastoma SH‐SY5Y
Author(s) -
Vaughan Peter F. T.,
Kaye David F.,
Reeve Helen L.,
Ball Stephen G.,
Peers Chris
Publication year - 1993
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1993.tb03501.x
Subject(s) - nicotinic agonist , mecamylamine , chemistry , nicotinic antagonist , endocrinology , sh sy5y , medicine , agonist , receptor , pharmacology , biology , biochemistry , neuroblastoma , cell culture , genetics
Dimethylphenylpiperazinium iodide (a nicotinic agonist) evokes noradrenaline release from human neuroblastoma SH‐SY5Y cells that have been pretreated with 12‐ O ‐tetradecanoylphorbol 13‐acetate for 8 min. This effect of dimethylphenylpiperazinium iodide was inhibited by 1 μ M mecamylamine but not by 1 μ M atropine, which suggests that SH‐SY5Y cells express nicotinic receptors coupled to the release of noradrenaline. Dimethylphenylpiperazinium iodide‐evoked release was enhanced by 5 μ M Bay K 8644 (an L‐type calcium agonist) and inhibited by 1 μ M nifedipine. Dimethylphenylpiperazinium iodide depolarised SH‐SY5Y cells and enhanced the level of intracellular calcium in cells loaded with fura 2. The effects of dimethylphenylpiperazinium iodide on noradrenaline release, depolarisation, and intracellular calcium levels were all inhibited by 1 μ M desmethylimipramine. The results of this study show that nicotinic receptors in SH‐SY5Y cells stimulate noradrenaline release by activation of L‐type calcium channels.